Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company, has announced that CEO Anish Bhatnagar will participate in a fireside chat at Oppenheimer’s 33rd Annual Healthcare Conference on March 14, 2023, at 11:20 AM Eastern Time. This participation highlights Soleno's commitment to transparency and engagement with investors. The event will be accessible via a live audio webcast, available on the company’s website. Soleno specializes in developing novel therapeutics for rare diseases, with its lead candidate, DCCR, currently undergoing Phase 3 clinical trials for Prader-Willi syndrome.

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 11:20 AM Eastern Time.

A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

FAQ

When will Soleno Therapeutics participate in the Oppenheimer Healthcare Conference?

Soleno Therapeutics will participate in the Oppenheimer’s 33rd Annual Healthcare Conference on March 14, 2023, at 11:20 AM Eastern Time.

Who is representing Soleno Therapeutics at the Oppenheimer Conference?

Anish Bhatnagar, M.D., the CEO of Soleno Therapeutics, will represent the company at the Oppenheimer Conference.

What is the focus of Soleno Therapeutics’ clinical development?

Soleno Therapeutics focuses on developing therapeutics for rare diseases, with its lead candidate being evaluated for Prader-Willi syndrome.

Where can I watch the Soleno Therapeutics fireside chat?

The fireside chat can be accessed via a live audio webcast on Soleno Therapeutics' website.

What is DCCR in relation to Soleno Therapeutics?

DCCR is Soleno Therapeutics’ lead candidate, a once-daily oral tablet being evaluated for the treatment of Prader-Willi syndrome.